Claus Vander Velden - 03 Nov 2026 Form 4 Insider Report for ANAVEX LIFE SCIENCES CORP. (AVXL)

Reporting relationship
Director
Issuer ticker
AVXL
Reported as of
03 Nov 2026
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
06 Nov 2026, 20:16:02 UTC
Prior SEC filing
02 Apr 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/Claus van der Velden
Filing notes and source

Key filing fact

Claus Vander Velden filed Form 4 for ANAVEX LIFE SCIENCES CORP. (AVXL) on 06 Nov 2026.

Key facts

  • This page summarizes Claus Vander Velden's Form 4 filing for ANAVEX LIFE SCIENCES CORP. (AVXL).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 06 Nov 2026, 20:16.

Change

  • Previous filing in this sequence was filed on 02 Apr 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001733908 Primary reporting owner

Velden Claus Vander

Relationship
Director
Address
630 5TH AVENUE 20TH FLOOR, NEW YORK
Signature
/s/Claus van der Velden
Signature date
06 Nov 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AVXL transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares
+50,000
Change %
Price
$0.000000*
Shares after
50,000
Date
03 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
50,000
Exercise price
$1.20
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option vests in three substantially equal annual installments beginning on March 31, 2027

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .